<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00796926</url>
  </required_header>
  <id_info>
    <org_study_id>R632/53/2008</org_study_id>
    <nct_id>NCT00796926</nct_id>
  </id_info>
  <brief_title>Trial to Compare the Efficacy of Systane Ultra and Refresh Drop in the Treatment of Dry Eye in Asian Eyes</brief_title>
  <official_title>Randomised Controlled Trial to Compare the Efficacy of Systane Ultra and Refresh Drop in the Treatment of Dry Eye in Asian Eyes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Louis Tong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Singapore National Eye Centre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Systane Ultra is at least as efficacious and safe as Refresh Tears in Asian people with Dry
      Eyes
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Comparison of efficacy of Systane Ultra and Refresh Tears
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Analog Score (VAS)</measure>
    <time_frame>6 weeks</time_frame>
    <description>Global score calculated from square root( square of (discomfort severityX Sqr(symptom frequency)) Scale from 0 to 100 higher value indicates more adverse symptoms each subscale severity or frequency also has same minimum and maximum</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Corneal Fluorescein Staining Score</measure>
    <time_frame>6 weeks</time_frame>
    <description>This is graded in the 5 zones of each cornea according to number of spots of corneal fluorescein staining, confluency of spots and presence of filaments if any</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tear Break Up Time (TBUT)</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Schirmer I Reading</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Meibography Grading</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tear Osmolarity</measure>
    <time_frame>6 weeks</time_frame>
    <description>This is measured by the TearLab (Ocusense) system</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Superior and Inferior Tear Meniscus Height</measure>
    <time_frame>6 weeks</time_frame>
    <description>This is determined by anterior segment OCT visante system</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Xerophthalmia</condition>
  <condition>Blepharitis</condition>
  <arm_group>
    <arm_group_label>Systane Ultra</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Used four times a day topically to each eye</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Refresh</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Used four times a day topically to each eye</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Systane Ultra eyedrops</intervention_name>
    <description>Four times a day</description>
    <arm_group_label>Systane Ultra</arm_group_label>
    <other_name>Systane Ultra, Alcon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Refresh eye drops</intervention_name>
    <description>Four times a day</description>
    <arm_group_label>Refresh</arm_group_label>
    <other_name>Refresh, Allergan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject age is between 40 and 65 years old.

          2. Corneal fluorescein staining present in at least one/five sectors of at least one
             cornea

          3. At least one question out of 6 questions on dry eye symptom present often or all the
             time.

             based on the Salisbury Eye study by Oliver Schein et al. (Does your eye feel dry,
             gritty, red, watery, crusted, stuck in the morning?) Please see appendix 1.

          4. At least one of the following: TBUT &lt;= 5 s or Schirmer I less than 8 mm in at least
             one eye

          5. Yamaguchi score 2 in at least one sector of one of 4 lids (slight advancement of
             Marx's line in line with Meibomian orifice)

          6. Not using non-lubricant ophthalmic drops within the last 30 days and able to abstain
             from non-trial topical eye medications for 6 weeks.

          7. Use of lubricants during the week before recruitment (ranging from 3 times in the week
             to less than 6 times a day every day).

          8. Able to use saline eyedrops during the 7 day 'washout' evaluative phase, between 3
             times over week to less than 6 times a day in all days.

        Exclusion Criteria:

          1. Known history of thyroid disorders (diagnosed by physician).

          2. Known history of Sjogren syndrome or rheumatoid arthritis (diagnosed by physician).

          3. No ocular surgery within 6 months and LASIK within 1 year.

          4. Any intake of central nervous system and hormonal drugs within last 30 days and
             inability to withhold such drugs for at least 6 weeks.

          5. Ocular surface diseases such as pterygium, or obvious lid/orbital disease with
             lagophthalmos.

          6. Anticipated necessity to wear contact lens in the duration of the study.

          7. Not living in the same household as another participant of the study.

          8. Any other specified reason as determined by clinical investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Louis Tong, FRCS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Singapore National Eye Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Singapore National Eye Center</name>
      <address>
        <city>Singapore</city>
        <zip>168751</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 21, 2008</study_first_submitted>
  <study_first_submitted_qc>November 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2008</study_first_posted>
  <results_first_submitted>June 20, 2011</results_first_submitted>
  <results_first_submitted_qc>July 19, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 12, 2011</results_first_posted>
  <last_update_submitted>October 4, 2011</last_update_submitted>
  <last_update_submitted_qc>October 4, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 7, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Singapore National Eye Centre</investigator_affiliation>
    <investigator_full_name>Louis Tong</investigator_full_name>
    <investigator_title>Clinician-Scientist, Consultant</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Blepharitis</mesh_term>
    <mesh_term>Xerophthalmia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Carboxymethylcellulose Sodium</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Systane Ultra</title>
          <description>four times a day for six weeks in each eye</description>
        </group>
        <group group_id="P2">
          <title>Refresh</title>
          <description>Four times a day for 6 weeks in each eye</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Systane Ultra</title>
          <description>four times a day for six weeks in each eye</description>
        </group>
        <group group_id="B2">
          <title>Refresh</title>
          <description>Four times a day for 6 weeks in each eye</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.2" spread="5.8"/>
                    <measurement group_id="B2" value="55.7" spread="5.5"/>
                    <measurement group_id="B3" value="55.9" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Singapore</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Visual Analog Score (VAS)</title>
        <description>Global score calculated from square root( square of (discomfort severityX Sqr(symptom frequency)) Scale from 0 to 100 higher value indicates more adverse symptoms each subscale severity or frequency also has same minimum and maximum</description>
        <time_frame>6 weeks</time_frame>
        <population>intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Systane Ultra</title>
            <description>four times a day for six weeks in each eye</description>
          </group>
          <group group_id="O2">
            <title>Refresh</title>
            <description>Four times a day for 6 weeks in each eye</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Analog Score (VAS)</title>
          <description>Global score calculated from square root( square of (discomfort severityX Sqr(symptom frequency)) Scale from 0 to 100 higher value indicates more adverse symptoms each subscale severity or frequency also has same minimum and maximum</description>
          <population>intention to treat</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.55" spread="16.8"/>
                    <measurement group_id="O2" value="27.27" spread="15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Corneal Fluorescein Staining Score</title>
        <description>This is graded in the 5 zones of each cornea according to number of spots of corneal fluorescein staining, confluency of spots and presence of filaments if any</description>
        <time_frame>6 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tear Break Up Time (TBUT)</title>
        <time_frame>6 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Schirmer I Reading</title>
        <time_frame>6 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Meibography Grading</title>
        <time_frame>6 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tear Osmolarity</title>
        <description>This is measured by the TearLab (Ocusense) system</description>
        <time_frame>6 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Superior and Inferior Tear Meniscus Height</title>
        <description>This is determined by anterior segment OCT visante system</description>
        <time_frame>6 weeks</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Systane Ultra</title>
          <description>four times a day for six weeks in each eye</description>
        </group>
        <group group_id="E2">
          <title>Refresh</title>
          <description>Four times a day for 6 weeks in each eye</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Louis Tong</name_or_title>
      <organization>Singapore National Eye Center</organization>
      <phone>65 62277255</phone>
      <email>Louis.tong.h.t@snec.com.sg</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

